MARC N. CASPER - 28 Oct 2024 Form 4 Insider Report for THERMO FISHER SCIENTIFIC INC. (TMO)

Role
Chairman & CEO, Director
Signature
/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper
Issuer symbol
TMO
Transactions as of
28 Oct 2024
Net transactions value
-$6,835,523
Form type
4
Filing time
30 Oct 2024, 16:08:20 UTC
Previous filing
05 Sep 2024
Next filing
01 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMO Common Stock Options Exercise $2,106,800 +10,000 +8.3% $210.68 131,192 28 Oct 2024 Direct
transaction TMO Common Stock Sale $717,444 -1,300 -0.99% $551.88 129,892 28 Oct 2024 Direct F1, F2
transaction TMO Common Stock Sale $1,188,800 -2,150 -1.7% $552.93 127,742 28 Oct 2024 Direct F1, F3
transaction TMO Common Stock Sale $1,824,151 -3,294 -2.6% $553.78 124,448 28 Oct 2024 Direct F1, F4
transaction TMO Common Stock Sale $169,190 -305 -0.25% $554.72 124,143 28 Oct 2024 Direct F1, F5
transaction TMO Common Stock Sale $770,574 -1,386 -1.1% $555.97 122,757 28 Oct 2024 Direct F1, F6
transaction TMO Common Stock Sale $649,371 -1,165 -0.95% $557.40 121,592 28 Oct 2024 Direct F1, F7
transaction TMO Common Stock Sale $223,380 -400 -0.33% $558.45 121,192 28 Oct 2024 Direct F1, F8
transaction TMO Common Stock Options Exercise $2,106,800 +10,000 +8.3% $210.68 131,192 29 Oct 2024 Direct
transaction TMO Common Stock Sale $521,829 -952 -0.73% $548.14 130,240 29 Oct 2024 Direct F1, F9
transaction TMO Common Stock Sale $758,915 -1,381 -1.1% $549.54 128,859 29 Oct 2024 Direct F1, F10
transaction TMO Common Stock Sale $2,087,155 -3,792 -2.9% $550.41 125,067 29 Oct 2024 Direct F1, F11
transaction TMO Common Stock Sale $1,475,343 -2,675 -2.1% $551.53 122,392 29 Oct 2024 Direct F1, F12
transaction TMO Common Stock Sale $607,651 -1,100 -0.9% $552.41 121,292 29 Oct 2024 Direct F1, F13
transaction TMO Common Stock Sale $55,321 -100 -0.08% $553.21 121,192 29 Oct 2024 Direct F1
holding TMO Common Stock 11,300 28 Oct 2024 By Alison Casper 2020 Irrevocable Trust F14
holding TMO Common Stock 43,608 28 Oct 2024 By Floral Park Associates, Inc.
holding TMO Common Stock 5,000 28 Oct 2024 By MNC 2020 Irrevocable Trust F15

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -10,000 -22% $0.000000 35,850 28 Oct 2024 Common Stock 10,000 $210.68 Direct F16
transaction TMO Stock Option (Right to Buy) Options Exercise $0 -10,000 -28% $0.000000 25,850 29 Oct 2024 Common Stock 10,000 $210.68 Direct F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.36 to $552.35, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.47 to $553.43, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.47 to $554.33, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.48 to $555.06, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.495 to $556.39, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $556.91 to $557.89, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $558.11 to $558.79, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.755 to $548.51, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.85 to $549.78, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.85 to $550.84, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.09 to $551.98, inclusive.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.21 to $553.20, inclusive.
F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.
F16 The option vested in four equal installments on February 27, 2019, 2020, 2021, and 2022.